Antihemophilic Factor: Its Presence in Fibrinogen, Assay Problems and the Stability of Lyophilized AHF-Fibrinogen Preparations

Werner Baumgarten; Benjamin E. Sanders; Benita D Belkin; Frank E Pagenkemper; William G Albers; Joseph L Ciminera

doi:10.1055/s-0038-1654990

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1963; 09(02): 354-367
DOI: 10.1055/s-0038-1654990

Originalarbeiten — Original Articles — Travaux Originaux

Schattauer GmbH

Antihemophilic Factor: Its Presence in Fibrinogen, Assay Problems and the Stability of Lyophilized AHF-Fibrinogen Preparations

Werner Baumgarten

¹Merck Institute for Therapeutic Research, Merck Sharp and Dohme Research Laboratories and Merck Sharp and Dohme Division of Merck & Co., Inc., West Point, Pennsylvania

,

Benjamin E. Sanders^*

¹Merck Institute for Therapeutic Research, Merck Sharp and Dohme Research Laboratories and Merck Sharp and Dohme Division of Merck & Co., Inc., West Point, Pennsylvania

,

Benita D Belkin

¹Merck Institute for Therapeutic Research, Merck Sharp and Dohme Research Laboratories and Merck Sharp and Dohme Division of Merck & Co., Inc., West Point, Pennsylvania

,

Frank E Pagenkemper

¹Merck Institute for Therapeutic Research, Merck Sharp and Dohme Research Laboratories and Merck Sharp and Dohme Division of Merck & Co., Inc., West Point, Pennsylvania

,

William G Albers

¹Merck Institute for Therapeutic Research, Merck Sharp and Dohme Research Laboratories and Merck Sharp and Dohme Division of Merck & Co., Inc., West Point, Pennsylvania

,

Joseph L Ciminera

¹Merck Institute for Therapeutic Research, Merck Sharp and Dohme Research Laboratories and Merck Sharp and Dohme Division of Merck & Co., Inc., West Point, Pennsylvania

› Institutsangaben

Abstract

Summary

The thromboplastin generation test of Biggs et al. and of Pitney, and adopted by Surgenor for the assay of antihemophilic factor activity in lyophilized preparations of human fibrinogen, has been modified to yield a selfcontained statistically valid assay. This procedure was designed to serve primarily as a control procedure. The AHF activity of production lots of human fibrinogen was assayed, and the stability of AHF under different conditions of storage was determined.

The procedure described in this paper is a satisfactory control procedure for AHF potency testing. In the absence of a generally recognized unit of AHF potency, it would seem most helpful to the clinician to have the potency related to the average activity in fresh normal human plasma.

Volltext

Referenzen

References
1 Biggs R, Douglas A. S. Thromboplastin generation test. J. clin. Path. 06: 23 1953;
2 Biggs R, Eveling J, Richards G. The assay of anti-haemophilic-globulin activity. Brit. J. Haemat. 01: 20 1955;
3 Biggs R, Macfarlane R. G. Prothrombin consumption test. In: Human Coagulation and its Disorders. 398 Blackwell: Oxford; 1957
4 Blombäck B, lombäck M. B. Purification of human and bovine fibrinogen. Arkiv Kemi. 10: 415 1956;
5 Cohn E. J, Strong L. E, Hughes Jr. W. L, Mulford D. J, Ashworth J. N, Melin M, Taylor H. L. Preparation and properties of serum and plasma proteins. IV. A system’ for separation into fractions of the protein and lipoprotein corttponents of biological tissues and fluids. J. Amer. chem. Soc. 68: 459 1946;
6 Didisheim P. An artificial reagent for the diagnosis of classical hemophilia. Science 129: 389 1959;
7 Enneking W. F. Elective surgery for the equine deformity of hemophilia. Presented before the Southern Medical Association Meeting; Dallas, Texas: 1961. (Submitted for publication to the “Annals of Surgery”)
8 Irwin A. R, Liles W. B, Blanchard R. J. Bladder neck obstruction in a sixmonth old hemophilic infant: Successful surgical repair with the aid of fibrinogen rich in Factor VIII. Presented before the Louisiana Medical Society, Monroe, La. May 8 and 9, 1962
9 Kekwick R. A, Walton P. L. Conditions influencing the stability of human antihaemophilic factor. Nature 194: 878 1962;
10 Lewis J. H, Didisheim P. Differential diagnosis and treatment of hemorrhagic disease. A.M.A. Arch. int. Med. 100: 157 1957;
11 McMillan C. W, Diamond L. K, Su’rgenor D. M. Treatment of classic hemophilia: The use of fibrinogen rich in Factor VIII for hemorrhage and for surgery. New Engl. J. Med. 265 224, 277 1961;
12 Nour-Eldin F. Stability of freeze-dried anti-haemophilic globulin. Nature 19: 503 1961;
13 Pitney W. R. The assay of antihaemophilic globulin (AHG) in plasma. Brit. J. Haemat. 02: 250 1956;
13a Rizza C. R. Effect of exercise on the level of antihemophilic globulin in human blood. J. Physiol. (Lond) 156: 128 1961;
14 Rodman N. F, Barrow E. M, Graham J. B. Diagnosis and control of the hemophilioid states with the partial thromboplastin time (PPT) test. Amer. T. clin. Path. 29: 525 1958;
15 Shulman N. R, Marder V. J, Hiller M. C. A new method for measuring minimum in vivo concentrations of Factor VIII applied in distribution and survival studies. Presented at 54th Annual Meeting of the American Society for Clinical Investigation. Atlantic City; April 29, 1962.
16 Surgenor D. M, McMillan C. W, Diamond L. K, Steele B. B. Studies with AHF-rich fibrinogen in classical hemophilia. Vox Sang. (Basel) 05: 80 1960;
17 Surgenor D. M, Wilson N. A, Henry A. S. Factor V from human plasma. Thrombos.Diathes. haemorrh. (Stuttg) 05: 1 1960;
18 Surgenor D. M, Steele B. B. Private communication.